Today's five run from a furniture retailer quietly stringing together growth quarters to a cybersecurity giant rebuilding around identity, with a genomics platform, a cancer drug developer and a 3D printing turnaround in between.
Haverty Furniture Companies (HVT): Furniture Retailer Strings Together Four Straight Growth Quarters
Havertys sells mid-to-upper-priced furniture across the South and Midwest, and it just posted a fourth straight quarter of comparable-store sales growth. The next read is whether that momentum holds with housing turnover still frozen.
View Chart →SOPHiA GENETICS (SOPH): First AstraZeneca Diagnostics Deals Open a New Lane
SOPHiA runs cloud software that helps hospitals read genomic data for cancer care, and it just signed its first two companion diagnostic programs with AstraZeneca. Watch whether biopharma becomes the growth engine under a brand-new CEO.
View Chart →ORIC Pharmaceuticals (ORIC): Prostate Cancer Program Moves Into Late-Stage Testing
ORIC develops cancer drugs aimed at the resistance that makes existing treatments stop working, and it has now launched its first global Phase 3 trial in advanced prostate cancer. The next milestone lands at the ESMO conference in October.
View Chart →3D Systems (DDD): Printer Sales Accelerate While the Turnaround Stays Unproven
3D Systems builds 3D printers for medical, dental, aerospace and data center customers, and hardware sales are accelerating after years of revenue decline. Watch whether those printers pull through recurring materials revenue; losses persist.
View Chart →Palo Alto Networks (PANW): Identity Security Becomes the Next Growth Pillar
Palo Alto sells the software that guards corporate networks and cloud systems, and its CyberArk deal put identity protection at the center of the strategy. The whole story lands September 1, the first full-year report with CyberArk inside.
View Chart →This newsletter is for informational purposes only and does not constitute financial advice. TradersPro and its contributors are not registered investment advisors. Always conduct your own due diligence before making investment decisions. Past performance is not indicative of future results.
